FTC Settlement with CVS Targets Insulin Price Manipulation
The FTC's proposed settlement with CVS aims to address allegations of price manipulation by its pharmacy benefit manager, potentially saving consumers $7 billion over the next decade.
The Federal Trade Commission (FTC) has proposed a settlement with CVS concerning allegations that its pharmacy benefit manager (PBM) manipulated insulin prices. This manipulation reportedly impeded access to affordable insulin for consumers.
The settlement is projected to save Americans up to $7 billion in out-of-pocket costs over the next ten years, indicating significant implications for healthcare affordability.
If implemented, this agreement may lead to structural changes in how insulin pricing is managed, potentially enhancing access and reducing financial burdens on consumers reliant on this essential medication.